Approval · Notice of Compliance 25697 · 2021
MINT-PREGABALIN: Notice of Compliance 25697
Issued April 20, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25697
- Date
- April 20, 2021
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Labelling Only
- Reason
- Updating the product monograph. labelling update to match licensor. update to labelling materials
- Canadian reference product
- LYRICA (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-PREGABALIN | Not yet assigned | — |
Medicinal ingredients
- PREGABALIN 25 MG per CAP
- PREGABALIN 50 MG per CAP
- PREGABALIN 75 MG per CAP
- PREGABALIN 100 MG per CAP
- PREGABALIN 150 MG per CAP
- PREGABALIN 200 MG per CAP
- PREGABALIN 225 MG per CAP
- PREGABALIN 300 MG per CAP